title: [Anti-obesity drugs: status quo and recent advances].
abstract: Obesity has become a major health problem worldwide. The prevalence and morbidity of obesity-related diseases including diabetes, hypertension, cerebro-cardiovascular diseases, and tumors also have remarkably increased. Treatment of obesity poses a challenge for clinicians. Anti-obesity treatment is helpful to improve and even reverse obesity-related complications. Diet control and physical exercises remain the predominant interventions for obese patients. Anti-obesity drugs can be considered in those who respond poorly to behavioral intervention or those who have developed obesity-related complications. The commonly used anti-obesity drugs include gastrointestinal lipase inhibitors and appetite suppressants. Glucagon-like peptide 1 has also been found to be effective in reducing body weight. Some more drugs are under development, which include selective 5-HT 2c agonist, β3 receptor agonist, and melanocortin receptor 4 agonist, may also be promising.
authors: Key Laboratory of Endocrinology of Ministry of Health, Department of Endocrinology,ʤPUMC Hospital, CAMS and PUMC, Beijing 100730, China.
authors: Hui-juan
authors: HJ
authors: Zhu
authors: Zi-meng
authors: ZM
authors: Jin
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1 / Q000627:therapeutic use; D006801:Humans; D009765:Obesity / Q000188:drug therapy*
chemical_list: D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D052216:Glucagon-Like Peptide 1